CVS director Mike Mahoney, whose day job is CEO of Boston Scientific, bought 30,000 shares of the healthcare company.

After underperforming throughout 2024, shares of CVS Health (NYSE: CVS) are surging. From the end of 2024 through Feb. 14, ...

Despite a recent 45% rally, I maintain a 'Sell' view on CVS due to its underwhelming execution record and rising leverage ...

CVS’s stock soared toward after its quarterly profit beat expectations by the widest margin in more than four years.

CVS Pharmacy thinks it has found a solution to customer complaints about locked display cases - but the cure may be worse ...

CVS Health (CVS) stock soared about 15% yesterday after posting upbeat fourth-quarter results, with revenues and earnings ...

Some analysts are more optimistic about CVS’ ability to navigate higher-than-expected medical costs in its insurance unit ...

Retail pharmacy chain CVS Health (CVS) is scheduled to announce its results for the fourth quarter of 2024 before the market ...

We recently compiled a list of the 10 Best Performing S&P 500 Stocks So Far in 2025. In this article, we are going to take a ...

CVS Health (NYSE:CVS – Free Report) had its price target lifted by JPMorgan Chase & Co. from $80.00 to $81.00 in a report ...

Principal Securities Inc. grew its holdings in shares of CVS Health Co. (NYSE:CVS – Free Report) by 3.2% during the fourth ...

CVS Health exceeded Q4 sales estimates with $97.71B revenue. The company projects 2025 revenue above $134B and expects ...